SKYLINEDX ANNOUNCES UPCOMING ORAL PRESENTATION AT THE 21ST INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH

About CP-GEP (Merlin test)CP-GEP is a non-invasive prediction model for cutaneous melanoma patients that combines clinicopathologic (CP) variables with gene expression profiling (GEP). This model is able to identify cutaneous melanoma patients at low-risk for nodal metastasis who may forgo the sentinel lymph node biopsy (SLNB) procedure. The CP-GEP model was developed by Mayo Clinic and SkylineDx BV and it has been clinically validated in multiple studies. More information (including references) may be obtained at www.falconprogram.com and merlinmelanomatest.com. The test has been launched in the United States and Europe as Merlin test. SkylineDx collaborates with diagnostic service providers globally to bring this test to market and increase patient access. In the United States, Tempus is commercializing Tempus Merlin test. Quest Diagnostics launched their own LDT version of the CP-GEP model in the United States under the brand name MelaNodal Predict™.

ROTTERDAM, Netherlands, 08/10/2024 (informazione.it - comunicati stampa - salute e benessere)

CP-GEP is a non-invasive prediction model for cutaneous melanoma patients that combines clinicopathologic (CP) variables with gene expression profiling (GEP). This model is able to identify cutaneous melanoma patients at low-risk for nodal metastasis who may forgo the sentinel lymph node biopsy (SLNB) procedure. The CP-GEP model was developed by Mayo Clinic and SkylineDx BV and it has been clinically validated in multiple studies. More information (including references) may be obtained at w ww.falconprogram.com and merlinmelanomatest.com. The test has been launched in the United States and Europe as Merlin test. SkylineDx collaborates with diagnostic service providers globally to bring this test to market and increase patient access. In the United States , Tempus is commercializing Tempus Merlin test. Quest Diagnostics launched their own LDT version of the CP-GEP model in the United States under the brand name MelaNodal Predict™.

SkylineDx is a biotechnology company focused on research & development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient's response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in Rotterdam. the Netherlands , complemented by a U.S. base of operations and a CAP/CLIA certified laboratory in San Diego California , USA. To learn more about SkylineDx, please visit www.skylinedx.com .

 

View original content: https://www.prnewswire.co.uk/news-releases/skylinedx-announces-upcoming-oral-presentation-at-the-21st-international-congress-of-the-society-for-melanoma-research-302270185.html